Vasodilatory signaling molecules may offer therapeutic benefits in chronic glomerular disease by counteracting the detrimental effects of vasoconstrictors like angiotensin II on mesangial cells.
No takes yet. Share an insight, caveat, or question.
Does not support practice change in kidney disease; leaves open therapeutic translation of vasodilatory pathways pending prospective trials.
L Buschhausen (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: